Nemus Bioscience Pitch Deck Teardown: A Deep Dive

Introduction and Market Positioning

Slide 1: Title Slide

The presentation opens with the Nemus Bioscience logo and their OTCQB ticker symbol: NMUS. The date is clearly marked as February 2017. The background image features laboratory test tubes, signaling a focus on clinical research and biotechnology. There is no tagline or mission statement on the cover slide, keeping the focus entirely on the corporate identity and its public trading status.

Slide 5: Nemus Cannabinoid Development Portfolio

This slide provides a comprehensive overview of the company's pipeline. It lists five distinct drug candidates and their target indications. NB1111 (Prodrug THC) targets Glaucoma with a projected global market size of $8 billion and is in the Pre-Clinical stage. NB1222 (Prodrug THC) targets Chemotherapy-Induced Nausea and Vomiting (CINV) with a $2 billion market, also in Pre-Clinical. The remaining three candidates— NB2111 , NB2222 , and NB3111 —target pain, ocular diseases, and MRSA respectively, with market sizes ranging from $6 billion to over $30 billion. All three are currently in the Research phase. The slide cites sources like IMS Midas and Transparency Market Research for these figures.

Technical Strategy and Delivery Mechanisms

Slide 9: Innovative Cannabinoid Formulations

Nemus outlines its technical differentiator here: improved drug delivery. The slide states that all licensed delivery options optimize their prodrug technology by enhancing bioavailability and avoiding first-pass liver metabolism . They list three specific delivery routes: Ocular delivery for glaucoma, Transmucosal delivery (suppositories and buccal patches) for CINV and CIPN, and Transmembranous delivery (nasal/transdermal) for anti-infectives like MRSA. This slide is critical as it explains the 'how' behind their clinical strategy.

Slide 13: The Glaucoma Market

Focusing on their lead candidate, this slide details the Glaucoma opportunity. It notes that the global market is $8 billion, with a $2.3 billion US market representing 32 million prescriptions. Key strategic points include a well-defined regulatory pathway and the potential for "urgent medical need" or "breakthrough therapy" FDA designations. Notably, the slide points out that over 50% of patients are "non-responders" who require two or more prescriptions, representing a significant gap in current care.

Slide 17: Ocular Tissue Concentration Data

This is a highly technical data slide showing the results of a PK-PD (pharmacokinetic-pharmacodynamic) comparison in rabbit eyes. The chart tracks drug concentration in various parts of the eye (aqueous humor, iris/ciliary body, etc.) over 120 minutes. The key takeaways listed are that the drug localizes to the ocular organs responsible for IOP (intraocular pressure) regulation and, crucially, no THC was detected in the plasma of the study animals even after five days of dosing. This supports their claim of localized delivery without systemic side effects.

Secondary Indications and Market Expansion

Slide 21: NB1222 for CINV

This slide addresses the Chemotherapy-Induced Nausea and Vomiting market. It cites 15 million global cancer cases, with 70-80% of chemotherapy recipients experiencing CINV. The slide mentions Dronabinol (a synthetic THC) as a competitor with over $110 million in annual sales. Nemus plans to develop a suppository version of their prodrug, NB1222, and intends to use the 505(b)(2) expedited regulatory pathway for its NDA filing.

Slide 25: CIPN Section Header

A simple transition slide for Chemotherapy-Induced Peripheral Neuropathy (CIPN), identifying NB2111 as an analogue of CBD. This indicates a shift from THC-based prodrugs to CBD-based analogues for pain management.

Slide 31: MRSA as a Global Concern

This slide uses a collage of news headlines from The Economist and Daily Herald to establish the severity of the MRSA (superbug) crisis. It frames the problem as a "global urgent health concern" and a "fatal menace," moving the deck's narrative from chronic disease management to acute infectious disease threats.

Slide 33: Anti-Infective Platform for MRSA

Nemus explains their approach to MRSA, stating they have successfully screened a library of cannabinoids for bactericidal activity. They have identified "cannabinoid cocktails" with synergistic activity against multiple MRSA strains. The slide notes their intention to broaden their IP estate with synthetic molecules and mentions a goal to partner the platform in the H1 2017 timeframe to accelerate development.

Leadership and Governance

Slide 37: Management - Cosmas N. Lykos, Esq.

The final slide in the provided set profiles the Executive Chairman and Co-founder. Lykos's background is heavily weighted toward legal, compliance, and corporate governance. His experience includes roles as General Counsel and Chief Compliance Officer at public companies like Oakley, Inc. and RemedyTemp, Inc. The bio emphasizes his experience in negotiating licensing deals and managing foreign subsidiaries, which aligns with the company's strategy of licensing technology and seeking developmental partners.

What Works in This Deck

The Nemus deck excels at market quantification . By breaking down the specific dollar value and prescription volume for each indication (Slides 5, 13, 21), they provide a clear picture of the upside. The inclusion of pre-clinical data (Slide 17) is also a strength, as it provides empirical evidence for their claims regarding localized delivery and the absence of systemic THC. Furthermore, the regulatory strategy is well-articulated; mentioning the 505(b)(2) pathway (Slide 21) shows that the management team has a pragmatic plan for reaching the market faster than a standard drug development cycle might allow.

What Is Missing

The most glaring omission in this 10-slide sample is a financial slide . There is no mention of current cash runway, burn rate, or the specific amount of capital being raised. While the company is public (OTCQB), an investor deck usually includes a use-of-funds breakdown. Additionally, while the management slide for the Executive Chairman is detailed, there are no slides for the scientific team or Chief Medical Officer in this selection. In a biotech play, the scientific pedigree is often as important as the legal/compliance background. Finally, there is a lack of competitive landscape analysis beyond a brief mention of Dronabinol; a more robust comparison against existing glaucoma or MRSA treatments would strengthen the case.

What a Founder Should Copy

Founders in the life sciences space should emulate the Pipeline Table on Slide 5. It is a standard but highly effective way to show breadth and progress simultaneously. The use of third-party validation for market sizes (citing IMS and Pew Trust) is also a best practice that builds credibility. Another strong element is the visual Abbreviation Key on Slide 17; when presenting complex data, providing a legend on the same slide helps keep the audience engaged without forcing them to flip back to previous pages. Lastly, the clear distinction between delivery mechanisms (Slide 9) helps non-technical investors understand the company's unique value proposition in a crowded field.